Study S001618

Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Combination With Semaglutide in Subjects Being Overweight or With Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT03600480
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 96
Start: 2018-07-25
Primary completion: 2020-06-12
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity; Overweight
Interventions: DRUG:NNC0174-0833; DRUG:Semaglutide; DRUG:Placebo (NNC0174-0833)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1203-6796

Registered primary outcomes

Number of treatment emergent adverse events (TEAEs) [From first administration of NNC0174-0833 (Day 1) to completion of the post-treatment follow-up (Day 176)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0014843	Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Enebo LB, Lancet (London, England)	2021	Randomized trial	PMID 33894838 DOI	cites ClinicalTrials.gov:NCT03600480; registry reference RESULT:33894838